Wiedmann Markus K H, Brunborg Cathrine, Di Ieva Antonio, Lindemann Kristina, Johannesen Tom B, Vatten Lars, Helseth Eirik, Zwart John A
a Department of Neurosurgery , Oslo University Hospital , Ulleval , Oslo , Norway.
b Neurosurgery Unit, Faculty of Medicine and Health Sciences , Macquarie University , Sydney , NSW , 2109 , Australia.
Acta Oncol. 2017 Oct;56(10):1302-1309. doi: 10.1080/0284186X.2017.1330554. Epub 2017 May 26.
In 2016, the International Agency for Research on Cancer (IARC) has announced that avoiding body fatness (i.e. overweight and obesity) contributes to prevent meningioma occurrence, but considered the available evidence for glioma inadequate. The association of body fatness with other CNS tumor subgroups is largely unknown.
To assess whether body fatness or body height are associated with risk for meningioma, glioma, pituitary adenoma (PA) or nerve sheath tumor (NST) in a large population-based Norwegian cohort.
In this prospective cohort study of 1.8 million Norwegian residents, weight and height were measured at baseline and incident intracranial tumors were subsequently identified by linkage to the Cancer Registry of Norway. Cox regression analyses were performed to estimate risk for each tumor subgroup in relation to anthropometric measures, stratified by sex and in different age groups.
During 54 million person-years of follow-up 3335 meningiomas, 4382 gliomas, 1071 PAs and 759 NSTs were diagnosed. Obesity (BMI ≥30 kg/m) was not associated with risk for meningioma or glioma, but was significantly associated with risk for PA (HR 1.43; 95% CI 1.09-1.88) compared with the reference group (BMI 20-24.9 kg/m). For intracranial NSTs, obesity was associated with reduced tumor risk (HR 0.68; 95% CI 0.46-0.99). Body height was associated with increased risk for all four tumor subgroups.
This study does not confirm overweight or obesity as risk factors for meningioma. Additionally, overweight and obesity can be quite confidently excluded as risk factors for glioma. However, this study indicates that body fatness increases the risk for PA, while it reduces the risk for NST.
2016年，国际癌症研究机构（IARC）宣布，避免身体肥胖（即超重和肥胖）有助于预防脑膜瘤的发生，但认为现有关于胶质瘤的证据不足。身体肥胖与其他中枢神经系统肿瘤亚组之间的关联在很大程度上尚不清楚。
在挪威一个基于人群的大型队列中，评估身体肥胖或身高是否与脑膜瘤、胶质瘤、垂体腺瘤（PA）或神经鞘瘤（NST）的风险相关。
在这项对180万挪威居民的前瞻性队列研究中，在基线时测量体重和身高，随后通过与挪威癌症登记处的关联识别出颅内新发肿瘤。进行Cox回归分析，以估计每个肿瘤亚组与人体测量指标相关的风险，并按性别和不同年龄组进行分层。
在5400万人年的随访期间，诊断出3335例脑膜瘤、4382例胶质瘤、1071例垂体腺瘤和759例神经鞘瘤。肥胖（BMI≥30kg/m²）与脑膜瘤或胶质瘤的风险无关，但与垂体腺瘤的风险显著相关（HR 1.43；95%CI 1.09-1.88），与参照组（BMI 20-24.9kg/m²）相比。对于颅内神经鞘瘤，肥胖与肿瘤风险降低相关（HR 0.68；95%CI 0.46-0.99）。身高与所有四个肿瘤亚组的风险增加相关。
本研究未证实超重或肥胖是脑膜瘤的危险因素。此外，可以相当有把握地排除超重和肥胖是胶质瘤的危险因素。然而，本研究表明，身体肥胖会增加垂体腺瘤的风险，而会降低神经鞘瘤的风险。
